There are 12,209 results relating to "Comprar en linda l"
Order by
|
SPICe briefings
Date published:
18 September 2018
Buying a home - Scottish Government support - Barriers to home ownership
Other barriers cited included the rising cost of living, properties in the area being too expensive and job insecurity.1Marshall, L., Wishart, R., & Smith, N. (2017, October 4).
Last updated:
19 April 2023
NHS Borders Evidence Pack
Dec-22 111 Jan-23 64 ae decision to treat M Referral to Treatment (RTT) - % 90% patient to be seen and treated within 18 weeks of n ↑ Dec-22 67.9% Jan-23 88.4% al treated within 18 weeks of referral referral. P l Diagnostics (8 key tests) - Number Zero patients waiting longer than 6 weeks for 8 key a ↑ Dec-22 1202 Jan-23 1073 n waiting >6 weeks diagnostic tests oita CAMHS- % treated within 18 weeks of r ↓ 90% patients seen and treated within 18 weeks of referral Nov-22 31.3% Dec-22 30.8% e referral pO A&E 4 Hour Standard - Patients l 95% of patients seen, discharged or transferred within 4 a ↑ discharged or transferred within 4 Dec-22 63.5% Jan-23 64.7% hours u hours nn Delayed Discharges - Patients A ↑ Zero patients delayed in hospital for more than 72 hours Dec-22 33 Jan-23 45 delayed over 72 hours Psychological Therapies - % treated ↓ 90% patient treated within 18 weeks of referral Nov-22 84.1% Dec-22 81.3% within 18 weeks of referral Drug & Alcohol - Treated within 3 ↔ 90% patient treated within 3 weeks of referral Nov-22 100% Dec-22 100% weeks of referral ↑ Sickness Absence Rates Maintain overall sickness absence rates below 4% Dec-22 6.41% Jan-23 6.91% 14 Cancer Waiting Times (please note there is a 1-month lag time for data) Fig. 9 95% of suspicion of cancer cases seen within 62 Days Percentage Mean UCL LCL Standard % 120% 110% 100% 90% 80% 70% 60% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 10 95% of cancer treatment patients treated within 31 Days Percentage Mean UCL LCL Standard % 105% 100% 95% 90% 85% 80% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M 15 Stage of Treatment- Outpatients Waiting Over 12 Weeks Stage of Treatment Target - Outpatients Waiting Over 12 Weeks 12wks Mean UCL LCL 8000 7000 6000 5000 4000 3000 2000 10000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n -1000 c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 11 16 Stage of Treatment- Inpatients Waiting Over 12 Weeks Stage of Treatment Target - Inpatients Waiting Over 12 Weeks 12wks Mean UCL LCL 2500 2000 1500 1000 5000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 12 17 Patients Treated within the 12 weeks Treatment Time Guarantee Patients Treated within the 12 weeks Treatment Time Guarantee 12wks TTG Mean UCL LCL 250 200 150 100 500 -50 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 13 18 18 Weeks Referral to Treatment Combined Pathway Performance 18 Weeks Percentage Referral to Treatment Combined Pathway Performance Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 14 19 Diagnostic Waits Diagnostics Waits over 6 Weeks Number over 6 weeks Mean UCL LCL 2000 1800 1600 1400 1200 1000 800 600 400 2000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 15 20 CAMHS Waiting Times- 18 Week Referral to Treatment 18 Week Referral to Treatment for CAMHS Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 16 21 Psychological Therapies Waiting Times- 18 Week Referral to Treatment 18 Week Referral to Treatment for Pyschological Therapies Percentage Mean UCL LCL Standard % 110% 90% 70% 50% 30% 10% -10% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 17 22 Delayed Discharges Fig. 18 23 Fig. 19 DDs at Census Delayed over 72 Hours DDs over 72 hours (3 days) Mean UCL LCL 70 60 50 40 30 20 100 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 20 Standard Delayed Bed Days Standard Delayed Bed Days Mean UCL LCL 2000 1500 1000 5000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M 24 Drugs & Alcohol 3 Week Drugs and Alcohol Referral to Treatment Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 21 25 Number of Alcohol Brief Interventions Delivered Trajectory Tolerance 2018/19 2020/21 2019/20 2020/21 2021/22 2022/23 2500 2000 1500 1000 5000 Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Fig. 22 26 Sickness Absence Sickness Absence Percentage below 4% 8% Percentage Mean UCL LCL Standard % 6% 4% 2% 0% … … … … … … … … … - - - - - - - - - 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 r r r r y y y y y 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 a a a a a a a a a - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r c c c c c v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n M M M M c c c c c u u u u u M M M M M p p p p p e e e e e o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N Fig. 23 Covid Absence Percentage Percentage Mean UCL LCL 6% 5% 4% 3% 2% 1% 0% -1% 0 1 2 0 1 2 0 1 2 0 1 2 0 1 1 2 2 3 0 1 2 0 1 2 0 1 2 1 2 0 1 2 1 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l t t t r r r r r c c c y y y v v v g g g p b p b p b n n n n n n u u u c c c a a p p p e e e a a a o o o u u u a a a e e e e e e u u u J J J J J J J J J O O O A A A S F S F S F D D D A A A N N N M M M M M Fig. 24 27 Smoking Quits (Please Note: All figures are cumulative.
SPICe briefings
Date published:
10 August 2023
Regulation of Legal Services (Scotland) Bill - Self-regulation, co-regulation and independent regulation
Retrieved from <a href="https://e-justice.europa.eu/29/EN/types_of_legal_professions#:~:text=discipline%20of%20lawyers.
SPICe briefings
Date published:
30 October 2019
Period Products (Free Provision) (Scotland) Bill - United States of America
Retrieved from <a href="https://www.globalcitizen.org/en/content/tampons-pads-girls-free-new-york-schools/" target="_blank">https://www.globalcitizen.org/en/content/tampons-pads-girls-free-new-york-schools/</a> [accessed 24 October 2019].
SPICe briefings
Date published:
22 October 2019
Competition policy - the UK framework and the impact of Brexit (republished) - EU and UK laws for the review of mergers and acquisitions
Retrieved from <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004R0139&from=EN" target="_blank">https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?
SPICe briefings
Date published:
25 August 2017
Brexit: Citizens' Rights and the Withdrawal Agreement - Council negotiating position
Retrieved from <a href="http://www.consilium.europa.eu/en/meetings/gac/2017/05/directives-for-the-negotiation-xt21016-ad01re02_en17_pdf/" target="_blank">http://www.consilium.europa.eu/en/meetings/gac/2017/05/directives-for-the-negotiation-xt21016-ad01re02_en17_pdf/</a> [accessed 15 August 2017] for the t...
SPICe briefings
Date published:
21 May 2020
The European Union's response to COVID-19
Retrieved from <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:12016E004" target="_blank">https://eur-lex.europa.eu/legal-content/EN/TXT/?
SPICe briefings
Date published:
17 January 2020
Negotiating the future UK and EU relationship - Key players
Retrieved from <a href="https://ec.europa.eu/commission/presscorner/detail/en/MEX_19_6146" target="_blank">https://ec.europa.eu/commission/presscorner/detail/en/MEX_19_6146</a> [accessed 5 December 2019].
SPICe briefings
Date published:
27 June 2022
Judicial Review - Key stages of a judicial review action
First, there is the permission stage, a significant hurdle to clear in practice,1Drummond, L., McCartney, F., & Poole, A. (2020).
SPICe briefings
Date published:
28 February 2022
Environmental Fiscal Measures for Scotland: - 5.4.5 Case Study: direct charges
The burning of waste in back gardens may become more common, a noted impact from PAYT in Ireland2Dunne, L., Convery, F.J., & Gallagher, L. (2008).
